These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Author: Gozzetti A, Candi V, Brambilla CZ, Papini G, Fabbri A, Bocchia M.
    Journal: Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038.
    Abstract:
    Abnormality of the B-cell receptor (BCR) signaling is correlated to origin of many B-cell malignancies. Bruton's tyrosine kinase (BTK), is described as a possible target in a many B-cell neoplasms. Ibrutinib is the most used inhibitor of BTK and has great tolerability and efficacy in chronic lymphocytic leukemia. This review summarizes results with ibrutinib in clinical trials and novel BTK inhibitors of interest.
    [Abstract] [Full Text] [Related] [New Search]